Articles |
From the Division of Cardiology (H.W.M., C.A.H., J.M.M., K.C., J.T.W.), University of Texas Health Science Center, Houston; the Center for Experimental Therapeutics (S.J.G.), Baylor College of Medicine, Houston, Tex; and the Department of Biomathematics (D.A.J.), M.D. Anderson Cancer Center, Houston, Tex.
Correspondence to Dr Howard W. Mueller, Division of Cardiology, University of Texas Health Science Center, 6431 Fannin St, Houston, TX 77030.
Abstract Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a potent phospholipid mediator of numerous inflammatory and thrombotic responses. The purpose of this study was to determine if PAF synthesis is elevated in damaged coronary arteries after a sustained period of cyclic flow variation (CFV), a phenomenon caused by alternating periods of thrombosis and reperfusion at sites of endothelial injury. Cyclic flow was established and maintained in the left anterior descending coronary arteries (LADs) of 10 dogs. After 8 hours of CFV, the section of damaged LAD containing the thrombus and control sections of the circumflex artery, carotid artery, and saphenous vein was excised, and the total lipids were extracted. The PAF was then purified by silica column chromatography and high-performance liquid chromatography and assayed by both a rabbit platelet bioassay and a PAF radioimmunoassay. With the platelet bioassay, PAF levels of 8.9±4.0 (range, 4.8 to 15.5) pg/mg wet wt were found in the damaged LADs from the 10 dogs. This PAF bioactivity was completely inhibited by a PAF receptor antagonist. When the radioimmunoassay was used, slightly higher PAF levels of 16.3±12.9 (range, 4.5 to 41.8) pg/mg wet wt were observed in the LADs. Overall, these PAF levels were 3- to 64-fold higher than in the control vessels when either assay method was used. Although increases in PAF were observed in the damaged LADs, measurements of PAF in blood samples taken from the LAD and the aorta (control) failed to demonstrate any site-specific increase of PAF in the blood. In related experiments, PAF was also measured in 23 endarterectomy samples taken from the coronary arteries of 16 patients with severe atherosclerosis. The PAF levels in these samples were highly variable (2.9±2.2 [range, 0.3 to 8.5] pg/mg wet wt) and showed no correlation with tissue mass, suggesting that PAF is affected by factors other than the simple presence of atherosclerotic tissue in the vessel. These findings provide direct evidence that PAF is synthesized locally at the site of endothelial injury during thrombosis and that PAF accumulates in the atherosclerotic plaque of some patients with advanced coronary artery disease.
Key Words: platelet-activating factor coronary thrombosis cyclic flow variations unstable angina atherosclerosis
This article has been cited by other articles:
![]() |
D. Nezic, A. Knezevic, S. Micovic, and M. Cirkovic eComment: Islets technique to reduce endarterectomized area included into graft during left anterior descending coronary artery endarterectomy Interactive CardioVascular and Thoracic Surgery, June 1, 2009; 8(6): 665 - 665. [Full Text] [PDF] |
||||
![]() |
D. C. Tsoukatos, I. Brocheriou, V. Moussis, C. P. Panopoulou, E. D. Christofidou, S. Koussissis, S. Sismanidis, E. Ninio, and S. Siminelakis Platelet-activating factor acetylhydrolase and transacetylase activities in human aorta and mammary artery J. Lipid Res., October 1, 2008; 49(10): 2240 - 2249. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Nezic, A. M. Knezevic, Z. D. Antonic, and M. Dj. Jovic Repair of Separated Coronary Segments Resulting From a Complicated Coronary Endarterectomy Ann. Thorac. Surg., November 1, 2007; 84(5): 1768 - 1770. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Arakawa, J.-Y. Qian, D. Baatar, K. Karasawa, Y. Asada, Y. Sasaguri, E. R. Miller, J. L. Witztum, and H. Ueno Local Expression of Platelet-Activating Factor-Acetylhydrolase Reduces Accumulation of Oxidized Lipoproteins and Inhibits Inflammation, Shear Stress-Induced Thrombosis, and Neointima Formation in Balloon-Injured Carotid Arteries in Nonhyperlipidemic Rabbits Circulation, June 21, 2005; 111(24): 3302 - 3309. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Turunen, J. Jalkanen, T. Heikura, H. Puhakka, J. Karppi, K. Nyyssonen, and S. Yla-Herttuala Adenovirus-mediated gene transfer of Lp-PLA2 reduces LDL degradation and foam cell formation in vitro J. Lipid Res., September 1, 2004; 45(9): 1633 - 1639. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Stangl, G. Baumann, K. Stangl, and S. B Felix Negative inotropic mediators released from the heart after myocardial ischaemia-reperfusion Cardiovasc Res, January 1, 2002; 53(1): 12 - 30. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Ruel, F. Wang, M. E. Bourke, J.-Y. Dupuis, J. A. Robblee, W. J. Keon, and F. D. Rubens Is tranexamic acid safe in patients undergoing coronary endarterectomy? Ann. Thorac. Surg., May 1, 2001; 71(5): 1508 - 1511. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Brocheriou, D. Stengel, L. Mattsson-Hulten, J. Stankova, M. Rola-Pleszczynski, F. Koskas, O. Wiklund, Y. Le Charpentier, and E. Ninio Expression of Platelet-Activating Factor Receptor in Human Carotid Atherosclerotic Plaques : Relevance to Progression of Atherosclerosis Circulation, November 21, 2000; 102(21): 2569 - 2575. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Montrucchio, G. Alloatti, and G. Camussi Role of Platelet-Activating Factor in Cardiovascular Pathophysiology Physiol Rev, October 1, 2000; 80(4): 1669 - 1699. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Kinn and R. J. Bache Effect of Platelet Activation on Coronary Collateral Blood Flow Circulation, October 6, 1998; 98(14): 1431 - 1437. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Tsoukatos, M. Arborati, T. Liapikos, K. L. Clay, R. C. Murphy, M. J. Chapman, and E. Ninio Copper-Catalyzed Oxidation Mediates PAF Formation in Human LDL Subspecies : Protective Role of PAF:Acetylhydrolase in Dense LDL Arterioscler Thromb Vasc Biol, December 1, 1997; 17(12): 3505 - 3512. [Abstract] [Full Text] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |